reported. Property-based optimization of high throughput screening hit 1 led to compounds with improved free exposure and in vivo muscle activation potency compared to the first-generation FSTA, tirasemtiv. Reldesemtiv demonstrated increased muscle force generation in a phase 1 clinical trial and is currently being evaluated in clinical trials for the treatment of amyotrophic lateral sclerosis.
据报道,reldesemtiv 是一种第二代快速骨骼肌肌
钙蛋白激活剂 (FSTA),可在次最大刺激频率下增加力的产生。与第一代 FSTA tirasemtiv 相比,基于特性的高通量筛选命中1优化导致化合物具有更好的游离暴露和体内肌肉激活效力。Reldesemtiv 在 1 期临床试验中证明了肌肉力量的产生增加,目前正在临床试验中评估治疗肌萎缩侧索硬化症。